|View printer-friendly version|
|Array BioPharma Announces Library Agreement with Asahi Chemical Industry Co., Ltd|
|BOULDER, Colo.—(Mar. 13, 2000)—Array BioPharma Inc. today announced that it has signed an agreement to provide Asahi Chemical Industry Co., Ltd. with access to small molecule libraries. Under the terms of this agreement, Asahi will gain access to libraries from Array on a semi-exclusive basis. Financial terms were not disclosed. |
Array creates libraries of approximately 100,000 novel small molecule compounds, derived from approximately 100 scaffolds, on an annual basis. Computational techniques, including Array’s proprietary RADICAL™ software, are used to design the approximately 100 sub-libraries with physiochemical properties that are biased towards creating drug candidates with superior development characteristics. RADICAL™ is a computational program that categorizes conserved structural binding motifs from known drugs with protein targets. Array’s collection of libraries are directed at a number of mechanistic target classes including: G-protein coupled receptors, nuclear receptors, enzymes and protein-protein interactions. Array employs state-of-the-art robotics using novel chemical building blocks in a parallel synthetic format to produce these highly pure, drug-like compounds.
“The unique characteristics of Array’s libraries make them very attractive to us,” said Dr. Hiroshi Hayashi, general manager of life sciences. “Their drug-like qualities and design towards specific mechanistic targets means they complement our existing libraries very well.”
“We are delighted to be working with Asahi to build its drug discovery libraries,” said Dr. David Snitman, Array’s vice president of business development and chief operating officer. “Our goal is to provide libraries with the potential to accelerate the drug discovery process. Asahi has recognized that our libraries can generate a hit that can readily converted into a lead candidate through rapid optimization techniques incorporated into our library design.”
Array is a privately held discovery research organization (DRO™) providing research services and products in all aspects of chemistry, high-throughput screening, structural biology and information management. Array complements the experience of its researchers with proprietary drug discovery tools, including unique sets of SAR related building blocks for automated lead explosion, pharmacophore-biased small molecule libraries, high-speed synthesis automation, X-ray crystallography and qualifying human drug metabolism assays. For additional information, visit the company’s web site at www.arraybiopharma.com.